Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma

BACKGROUND: Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the...

Descripción completa

Detalles Bibliográficos
Autores principales: Woof, Victoria G., Lee, Rebecca J., Lorigan, Paul, French, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927744/
https://www.ncbi.nlm.nih.gov/pubmed/35301436
http://dx.doi.org/10.1038/s41416-022-01766-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927744/
https://www.ncbi.nlm.nih.gov/pubmed/35301436
http://dx.doi.org/10.1038/s41416-022-01766-x

Ejemplares similares